Yuhan Past Earnings Performance
Past criteria checks 5/6
Yuhan has been growing earnings at an average annual rate of 2.8%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 5.5% per year. Yuhan's return on equity is 7.5%, and it has net margins of 8.2%.
Key information
2.8%
Earnings growth rate
2.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 5.5% |
| Return on equity | 7.5% |
| Net Margin | 8.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Yuhan makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,008,841 | 165,686 | 384,162 | 197,701 |
| 30 Jun 24 | 1,893,119 | 147,849 | 385,446 | 146,919 |
| 31 Mar 24 | 1,860,529 | 124,466 | 378,998 | 130,975 |
| 31 Dec 23 | 1,858,984 | 133,993 | 370,027 | 119,920 |
| 30 Sep 23 | 1,872,336 | 88,109 | 365,050 | 117,355 |
| 30 Jun 23 | 1,820,811 | 76,045 | 350,511 | 114,124 |
| 31 Mar 23 | 1,808,041 | 101,446 | 355,579 | 111,826 |
| 31 Dec 22 | 1,775,847 | 95,144 | 356,575 | 107,103 |
| 30 Sep 22 | 1,749,315 | 74,669 | 359,069 | 116,405 |
| 30 Jun 22 | 1,769,245 | 97,836 | 362,073 | 112,866 |
| 31 Mar 22 | 1,719,630 | 97,911 | 355,095 | 108,107 |
| 31 Dec 21 | 1,687,810 | 102,583 | 346,977 | 106,677 |
| 30 Sep 21 | 1,725,261 | 98,128 | 350,567 | 121,027 |
| 30 Jun 21 | 1,703,475 | 97,833 | 333,638 | 128,767 |
| 31 Mar 21 | 1,685,623 | 97,578 | 321,279 | 141,056 |
| 31 Dec 20 | 1,619,865 | 192,761 | 309,459 | 142,634 |
| 30 Sep 20 | 1,552,188 | 184,730 | 292,514 | 124,020 |
| 30 Jun 20 | 1,504,765 | 168,667 | 292,671 | 109,357 |
| 31 Mar 20 | 1,448,677 | 140,227 | 291,603 | 96,264 |
| 31 Dec 19 | 1,480,354 | 40,006 | 298,249 | 96,900 |
| 30 Sep 19 | 1,500,782 | 44,230 | 295,958 | 84,846 |
| 30 Jun 19 | 1,497,130 | 41,438 | 289,460 | 86,652 |
| 31 Mar 19 | 1,523,954 | 52,333 | 285,113 | 81,152 |
| 31 Dec 18 | 1,518,823 | 57,481 | 272,199 | 74,067 |
| 30 Sep 18 | 1,481,906 | 70,146 | 260,112 | 78,217 |
| 30 Jun 18 | 1,482,034 | 84,572 | 255,011 | 72,563 |
| 31 Mar 18 | 1,450,870 | 100,288 | 254,545 | 70,132 |
| 31 Dec 17 | 1,462,248 | 109,034 | 251,733 | 71,435 |
| 30 Sep 17 | 1,434,749 | 139,325 | 247,128 | 63,536 |
| 30 Jun 17 | 1,417,835 | 137,434 | 242,253 | 60,608 |
| 31 Mar 17 | 1,395,518 | 139,440 | 233,210 | 57,434 |
| 31 Dec 16 | 1,320,797 | 161,249 | 228,048 | 52,667 |
| 30 Sep 16 | 1,274,011 | 134,997 | 229,655 | 50,435 |
| 30 Jun 16 | 1,223,925 | 155,819 | 221,368 | 48,078 |
| 31 Mar 16 | 1,163,130 | 152,682 | 209,371 | 43,881 |
| 31 Dec 15 | 1,128,731 | 126,047 | 206,756 | 39,016 |
| 30 Sep 15 | 1,097,229 | 118,104 | 199,135 | 34,597 |
| 30 Jun 15 | 1,046,716 | 98,362 | 199,297 | 30,754 |
| 31 Mar 15 | 1,031,875 | 94,628 | 202,271 | 31,270 |
| 31 Dec 14 | 1,017,492 | 90,948 | 202,259 | 30,915 |
| 30 Sep 14 | 1,007,109 | 95,434 | 200,307 | 31,018 |
| 30 Jun 14 | 970,253 | 87,696 | 192,807 | 31,896 |
| 31 Mar 14 | 953,191 | 83,863 | 193,993 | 31,378 |
| 31 Dec 13 | 943,609 | 86,461 | 192,515 | 32,027 |
Quality Earnings: A000105 has high quality earnings.
Growing Profit Margin: A000105's current net profit margins (8.2%) are higher than last year (4.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A000105's earnings have grown by 2.8% per year over the past 5 years.
Accelerating Growth: A000105's earnings growth over the past year (88%) exceeds its 5-year average (2.8% per year).
Earnings vs Industry: A000105 earnings growth over the past year (88%) exceeded the Pharmaceuticals industry 20.6%.
Return on Equity
High ROE: A000105's Return on Equity (7.5%) is considered low.